Supplementary Figure 1 from CD4+ T Cells Mediate MHC-Deficient Tumor Rejection and Endothelial Cell Reprogramming

Samuel I. Kim; Margaret E. Haerr; Maryam Al-Ghezi; Canping Chen; Yi Zhang; Jackie L. Phipps; Charu Arora; Kyle P. Gribbin; G.T. Kim; Nune Markosyan; Zheng Xia; Robert H. Vonderheide; Katelyn T. Byrne

doi:10.1158/2326-6066.31024062

Supplementary Figure 1 from CD4+ T Cells Mediate MHC-Deficient Tumor Rejection and Endothelial Cell Reprogramming

2026 Open access

Read full text

Authors: Samuel I. Kim, Margaret E. Haerr, Maryam Al-Ghezi, Canping Chen, Yi Zhang, Jackie L. Phipps, Charu Arora, Kyle P. Gribbin, G.T. Kim, Nune Markosyan, Zheng Xia, Robert H. Vonderheide

+1 more

Katelyn T. Byrne

DOI: 10.1158/2326-6066.31024062

Cited by: 0

Abstract

Supplementary Figure 1. Anti-CD40/ICB immunotherapy slows tumor growth in a CD4+ T cell-dependent, but CD8+ T cell- and NK1.1 cell-independent manner.

Fields of Study & Subjects

CAR-T cell therapy research Immune Cell Function and Interaction Cancer Immunotherapy and Biomarkers

Publication details

Publication date: 8 January 2026